New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies

Not yet recruiting

• Conditions: BK Virus Infection

• Registration Number: NCT05264259
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

BK virus (BKV) infection has a major negative impact on transplant recipients. No BKV-specific antiviral therapy is available, so there is an urgent need to develop new anti-BKV preventive and therapeutic strategies.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-02
• Study First Submitted: 2022-02-07
• Study First Submitted QC: 2022-02-21
• Last Update Submitted: 2022-02-21
• Study First Posted: 2022-03-03
• Last Update Posted: 2022-03-03
• Study Start: 2022-03-05
• Primary Completion: 2022-03-05
• Study Completion: 2025-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• BK positive
• adult
• ok to participed to research

Exclusion Criteria

• under guardianship
• under curatorship
• opposed to research
• deprived of liberty

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ability of the isolated monoclonal antibodies to neutralize all 3 BKV genotypes	5 years	The neutralization titer will be defined as the dilution of the sample that produced 50% inhibition of pseudovirion infectivity (IC50)

Trial Locations

Locations (1)

Service de Virologie - CHU Strasbourg - France; 🇫🇷 Strasbourg, France